Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
European Institue of Oncology, Department of Experimental Oncology, Milan, Italy. gioacchino.natoli@ifom-ieo-campus.it
Once regarded as an irreversible modification, the methylation of histone protein tails has recently been highlighted following the identification of enzymes capable of histone demethylation in response to developmental or environmental cues. An awareness of the dynamic nature of histone modification has stimulated interest in the concept that drugs targeting histone methylation/demethylation might provide treatments for cancer, inflammation and metabolic disorders. However, epigenetic therapies that target histone demethylation are at the concept stage. Histone demethylases and their potential as therapeutic targets are discussed in this review.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on